Mutations in BRAF activate oncogenic MAPK signalling in almost half of cutaneous melanomas. Inhibitors of BRAF (BRAFi) and its target MEK are widely used to treat melanoma patients with BRAF mutations but unfortunately acquired resistance occurs in the majority of patients. Resistance results from mutations or non-genomic changes that either reactivate MAPK signalling or activate other pathways that provide alternate survival and growth signalling. Here, we show the histone deacetylase inhibitor (HDACi) panobinostat overcomes BRAFi resistance in melanoma, but this is dependent on the resistant cells showing a partial response to BRAFi treatment. Using patient-and in vivo-derived melanoma cell lines with acquired BRAFi resistance, we show that combined treatment with the BRAFi encorafenib and HDACi panobinostat in 2D and 3D culture systems synergistically induced caspase-dependent apoptotic cell death. Key changes induced by HDAC inhibition included decreased PI3K pathway activity associated with a reduction in the protein level of a number of receptor tyrosine kinases, and cell line dependent upregulation of pro-apoptotic BIM or NOXA together with reduced expression of anti-apoptotic proteins. Independent of these changes, panobinostat reduced c-Myc and pre-treatment of cells with siRNA against c-Myc reduced BRAFi/HDACi druginduced cell death. These results suggest that a combination of HDAC and MAPK inhibitors may play a role in treatment of melanoma where the resistance mechanisms are due to activation of MAPK-independent pathways.
Introduction
Aberrant activation of the mitogen-activated protein kinase (MAPK) pathway which signals via ERK is a major feature in most melanoma, and 35-50% of melanoma tumours harbour an oncogenic activating mutation in BRAF. 1, 2 Drugs that specifically target BRAF proteins with activating V600 mutations have been a major breakthrough in melanoma treatment. These drugs have response rates of over 80%, but have been plagued by the relatively quick emergence of resistance. [3] [4] [5] Combined treatment with BRAF and MEK inhibitors reduces or delays the emergence of resistance 5, 6 but acquired resistance remains a significant problem. Many resistance mechanisms have been demonstrated but in general they have been categorised as those that lead to reactivation of the MAPK pathway and those that are MAPK pathway independent. 7 Mechanisms of MAPK reactivation of the pathway include mutations in NRAS, NF1 and MEK, increased expression of c-RAF or BRAF, and altered BRAF splicing.
components of the pathway such as AKT or PI3KCA. [16] [17] [18] Receptor tyrosine kinases can signal via either or both the MAPK and PI3K pathways and aberrant activation or upregulation of one or more RTK, including AXL, HGF/MET, PDGFR and the EGFR family may result in resistance to BRAF inhibitors. 9, [19] [20] [21] [22] [23] [24] Another resistance pathway involves a melanocyte lineage program that signals though CREB and MITF -this pathway could be suppressed by histone deacetylase inhibitors. 13, 25 Non-genomic alterations can also confer resistance and have been identified in approximately half of the tumours from patients with MAPKi resistant melanoma. 26 The nongenomic changes frequently involved changes in DNA methylation and were more consistent across different melanoma than those due to mutations. They were associated with upregulation in the tumour or its stroma of genes such as c-MET, IL-8 and NF-kB and downregulation of Wnt and RTK genes such as AXL and EGFR -in contrast to other reports that AXL and EGFR may be upregulated in resistance. 21, 24, 27 We have reported previously that treatment of melanoma with HDAC inhibitors can reverse resistance to BRAF inhibitors [28] [29] [30] and can potentiate treatment of melanoma with bromodomain and extra terminal (BET) inhibitors. 31 In our study, we have examined which BRAF resistant melanoma subtype responds best to the combination of BRAFi and HDACi. We find that combining HDAC inhibitor panobinostat (LBH589) with the BRAF-inhibitor encorafenib (LGX818) was most effective in melanoma with acquired resistance characterised by lack of MAPK pathway reactivation. Induction of cell death was associated with cell line specific changes in Bcl-2 family members, PI3K signalling, MITF, c-Myc and caspase activation. We suggest these results will help select patients likely to respond to this combination and extend the duration of responses to targeted therapy.
Material and Methods

Cell lines
Primary melanoma cell lines CM150-, CM145-, CM142-, CM143-cell lines were established from four patients entered into the Roche "BRIM2" phase II study of vemurafenib in patients. The cell lines were established from tumour biopsies prior to treatment and during relapse from treatment with vemurafenib, labelled "pre" and "post," respectively. These studies were approved by the Hunter and New England Analysis of cell death, cell cycle and mitochondrial membrane potential
The following assays were measured using a BD FACSCantoII flow cytometer. Apoptotic cells were quantified using Annexin-V/propidium iodide staining as described by the manufacturer (Becton Dickinson, Franklin Lakes, NJ, CA 35 Genes with insufficient signal were filtered out. For heatmaps, differential protein expression was calculated by subtracting log2 transformed protein levels of control (DMSO) treated cells from treated cells.
Western blotting
Western blot analysis was carried out as described previously. 36 Labelled bands were detected by Clarity horseradish peroxidase chemiluminescence kit (Bio-Rad, Hercules, CA), and images were captured with the ChemidocMP image system 
3D spheroid cultures
The 3D melanoma spheroid model mimics in vivo tumour architecture and microenvironment and is used for investigating growth, invasion and viability of melanoma cells. 37 Spheroids were prepared using the liquid overlay method as described 38, 39 and six spheroids embedded in collagen per treatment. After embedding media was added on top of the collagen layer containing the indicated drugs (final concentration of drugs was 1 mM encorafenib and 35 nM panobinostat). Following 3 days of treatment, spheroids were photographed, dissociated and stained with PI to measure cell death by flow cytometry.
In vivo experiments and immunohistochemistry
All animal experiments were performed in accordance with the 
Results
BRAF-inhibitor resistant melanoma can be re-sensitised by HDAC inhibitors
We examined the effect of combining inhibitors of BRAF and HDAC in four BRAFi-resistant melanoma cell lines established from patients relapsing and progressing after treatment with single-agent BRAF inhibitors. These four cell lines are denoted by a "post" suffix and three have matching cell lines established from the same patient before commencing BRAFi treatment -denoted by a "pre" suffix. Known mutations harboured by the cell lines are presented in Supporting Information Table S1 . The BRAFi-resistant cell lines were treated with the BRAF inhibitor encorafenib (encor) and/or the pan-HDACinhibitor panobinostat (pano). Combining encorafenib and panobinostat induced much higher levels of cell death in CM150-post and CM145-post cells (Fig. 1a) than either drug alone, a small increase in cell death in CM142-post cells and no increase in CM143-post cells. Neither drug, alone nor in combination caused cell death in normal human melanocytes (Fig. 1a) . Encorafenib induced some cell death in CM150-post cells, although these levels were much lower than those induced by the same treatment in the matched CM150-pre cell line (Supporting Information Fig. S1a ).
To determine if the drugs were acting synergistically, we treated cells with 6 concentrations of encorafenib or panobinostat, or a combination of both at a fixed ratio and measured cell death after 48 hr. We used the Chou and Talalay method to calculate a combination index -a measure of synergy where values <1 indicate synergy. 34 Combining encorafenib and panobinostat was highly synergistic in CM150-post and CM145-post cells, with a combination index <0.1 (Figs. 1b and 1c) . The combination was also moderately synergistic in CM142-post cells (Fig. 1c) . Combination index was not calculated for CM143-post cells as even high concentrations of encorafenib and panobinostat (9 mM and 270 nM respectively) did not induce 50% cell death.
Activity of combined HDAC and BRAF inhibitors against resistant melanoma grown in spheroids or as xenografts
We then sought to test the efficacy of combined BRAFi and HDACi in vivo. The cell lines most sensitive to the combination, CM150-post and CM145-post, did not efficiently form xenograft tumours in NOD-SCID mice. CM142-post cells, which showed moderate in vitro sensitivity to combined BRAF 1 HDAC inhibition, formed tumours and these cells were xenografted into NOD-SCID mice. Mice were treated for 21 days with encorafenib and/or panobinostat or carrier control and tumour growth measured (Fig. 2a) . Encorafenib treatment alone reduced tumour growth, in agreement with clinical observations that continuing BRAFi treatment slows tumour growth in patients with acquired BRAFi resistance. 6, 40 Panobinostat treatment alone reduced tumour size by 64%. Combining encorafenib and panobinostat did not reduce tumour volumes significantly more than panobinostat alone, although a slight trend to smaller tumours was observed. Immunohistochemistry on tumours harvested at the experimental endpoint (Supporting Information Figs. S1e-S1g) showed ongoing apoptosis in encorafenib treated mice only. Necrosis was observed in control-treated mice, consistent with the larger tumours in these mice. The lack of apoptosis in panobinostat or combination treated mice suggest that the treatment was mainly cytostatic in this model, or that apoptosis was not occurring at this time point. The lack of synergy of the agents in vivo against CM142-post xenografts was in keeping with the modest induction of apoptosis the combination induced in this cell line in culture (Fig. 1a) .
In vivo tests of the drug combination on xenografts of a BRAFi-na€ ıve (sensitive) cell line (CM138) showed that both encorafenib and panobinostat, alone or in combination, lead to complete regression in tumours (Supporting Information  Fig. S1b ). There was no significant difference between Although CM150-post and CM145-post cells did not form xenograft tumours, CM150-post (but not CM145-post) formed spheroids, and we used this model to extend our results from 2D culture. CM150-post cells were grown as spheroids, embedded in collagen matrix and treated with encorafenib and/or panobinostat for 96 hr. Only spheroids treated with the combination of drugs showed central clearing of the spheroid, indicative of cell death and spheroid disintegration (Fig. 2b) . Using flow cytometry we found spheroids treated with the combination of encorafenib and panobinostat had reduced viability, while control or single drug treatment did not lead to significant loss of viability (Fig. 2c) . While conducting these experiments we noted that spheroids treated with panobinostat, alone or in combination with encorafenib, demonstrated increased invasive behaviour, with greater migration of cells into surrounding matrix (Fig. 2b) .
Combined HDACi and BRAFi treatment induces caspase dependent death, mitochondrial depolarisation and is mediated by Class I HDAC We then explored the mechanism of cell death caused by combined HDAC and BRAF inhibition. Inhibition of caspases with the pan-caspase inhibitor Q-VD-OPh completely abrogated cell death (Fig. 3a) . Cell death was associated with depolarisation of mitochondrial outer-membrane potential (DMOMP), which was not prevented by caspase inhibition (Fig. 3b) . Together these data suggest apoptosis occurred via the intrinsic apoptotic pathway rather than by caspase 8/tBid activation.
Panobinostat inhibits all classes of HDACs. To elucidate which HDAC class was contributing to the resensitisation of BRAFi resistant cells, we treated cells with inhibitors specific to Class I HDAC (mocetinostat) or Class II HDAC (MC1568). Only mocetinostat allowed resensitisation to BRAFi, implicating the Class I HDAC (HDAC1, 2, 3, 8) in this process (Fig. 3c) .
HDACi reversed BRAFi-resistance in melanoma without MAPK pathway reactivation Next we asked why only some cell lines responded well to the drug combination. Acquired resistance to BRAF or BRAF 1 MEK inhibitors is associated with reactivation of MAPK signalling in 50-90% of patients. 14, 15, 41 We examined MAPK signalling in our BRAFi-resistant cell lines and found encorafenib strongly inhibited MAPK signalling in CM150-post and CM145-post cells, as shown by reduced levels of pERK and its target p-p90RSK (Fig. 4a) . The MEK2-K61E mutation in CM145-post cells (Supporting Information Table  S1 ) did not prevent encorafenib from reducing MAPK signalling suggesting this mutation only confers weak MEK activity. In CM142-post cells, encorafenib did not repress pERK but reduced p-p90RSK slightly, suggesting slight repression of MAPK signalling. There was no reduction in pERK or p-p90RSK in CM143-post. This cell line harbours an activating MEK1 E203K mutation, which allows constitutive MAPK activity in the absence of MEK phosphorylation. Panobinostat did not affect MAPK signalling (Fig. 4a) . The suppression of MAPK signalling by encorafenib was reflected by alterations in cell cycle. CM150-post and CM145-post cells exhibited a reduced S-phase population and increased G1 population following encorafenib treatment, while these changes were only moderate in CM142-post cells and very slight in CM143-post cells (Supporting Information Fig. S2a) .
These results suggested HDACi could resensitise melanoma to BRAFi only in cell lines that exhibited some decrease in MAPK signalling following BRAFi treatment. To further investigate this hypothesis we investigated the drug combination in three clones of SK-Mel28 melanoma cells that were selected for BRAFi resistance by long-term in vitro treatment with the BRAFi dabrafenib. 32, 33 Identified resistance mechanisms were NRAS Q61K; COT amplification and increased RTK expression for the BR2; BR4 and BR8 clones respecitvely (Supporting Table S1 ). 32, 33 The parental SK-Mel28 cells were sensitive to BRAFi and showed an induction of cell death, increased G1 population and reduced S-phase following encorafenib treatment (Fig. 4b, Supporting Information Fig. S2b ). While panobinostat did not induce apoptosis in these cells, it did increase cell death in response to encorafenib (Fig. 4b) . In BRAFiresistant clones, adding panobinostat treatment to encorafenib treatment increased cell death in BR4 cells, slightly in BR8 cells but not in BR2 cells (Fig. 4b ). This correlated with the ability of encorafenib to suppress MAPK signalling and induce cell cycle arrest -encorafenib reduced p-p90RSK and suppressed cells in S-phase predominantly in the parental and BR4 cells (Fig. 4c, Supporting Information  Fig. S2b) . Together, these results suggest that combined inhibition of HDAC and BRAF was most effective in melanoma cells where MAPK-signalling can still be repressed by BRAFi. There was no evidence that HDACi reduced MAPK signalling, which suggests that the HDAC inhibition suppresses MAPK-independent escape mechanisms or alters the balance of apoptotic proteins towards a pro-apoptotic state.
Apoptosis is dependent on upregulation of Bim or NOXA and downregulation of anti-apoptotic proteins Bcl-XL, Mcl-1 and XIAP
To understand the mechanisms involved in cell death we carried out Western blotting of cell lysates from CM150-post and CM145-post cells after 24 hr of drug treatment (Fig. 5a ). As expected, combined treatment with both encorafenib and panobinostat induced cleavage of caspase 3/7 and PARP in both cell lines, further supporting the suggestion that death was caspase driven.
The drugs induced a number of changes in expression of Bcl2 family proteins, but the magnitude of these changes was often cell line specific. For example, the pro-apoptotic BIM protein was strongly upregulated by encorafenib in CM150-post cells, but in CM145-post cells baseline and induced levels of BIM were much lower (Fig. 5a ). Baseline expression of the pro-apoptotic NOXA protein was much higher in CM145-post cells than CM150-post cells, and was reduced following encorafenib treatment, in agreement with previous reports 42 (Fig. 5a ). While panobinostat did not alter NOXA levels alone, it partially inhibited NOXA suppression caused by encorafenib. As the drug combination resulted in higher NOXA levels compared to encorafenib treatment alone, we hypothesised that NOXA may be contributing to the synergistic action of the drug combination. We used siRNA to investigate the contribution of BIM and NOXA to induction of apoptosis. As expected from the above observations (CM150-post cells have high BIM and low NOXA, and the inverse for CM145-post), BIM contributed to death induced in CM150-post cells, but not CM145-post cells, while the inverse was true for NOXA (Figs. 5b and 5c) .
XIAP, Bcl-XL and Mcl-1 were also decreased in the combination treated cultures particularly in CM145-post cells which would be expected to increase apoptosis (Fig. 5a ). Levels of BAX, BAK, PUMA and Survivin were not affected by the drug treatments (Supporting Information Fig. S3a ).
Previous studies reported that NOXA was upregulated by c-Myc in melanoma. 43 However BRAFi and HDACi treatment, alone or in combination, reduced levels of c-Myc, and levels of NOXA could not be related to c-Myc expression levels (Fig. 5a ). Despite this, downregulation of c-Myc by siRNA prior to drug treatment did reduce apoptosis in CM145-post cells (Supporting Information Figs. S3b and S3c), suggesting a role for c-Myc. MITF is also a candidate for mediating the effects of HDAC inhibition -MITF has previously been reported to increase Bcl-2 levels 44 and its upregulation is related to a drug-tolerant state. 13 Low levels of MITF have also been reported to be associated with resistance to BRAFi. 27, 45 We found MITF was reduced by HDAC inhibition in the CM145-post cell line, as has previously been reported. However MITF was expressed at very low levels in CM150-post cells (Fig. 5a ), casting doubt that reduced MITF mediates HDACi-induced drug sensitivity in all melanoma.
HDACi reduce RTKs and PI3K pathway signalling to synergise with BRAFi
We analysed changes in a larger number of proteins using RPPA analysis on cell lysates of CM150-and CM142-post cells treated with DMSO, encorafenib, panobinostat or combination (Fig. 6a, Supporting Information Fig. S4 ). Combination drug treatment reduced components and targets of the MAPK pathway (MEK-pS219S221; ERK-pT202_Y204), PI3K
pathway (PRAS40-pT246) or both pathways (p70S6K-pT389; S6-pS240_S244; S6-pS235_S236). RPPA studies suggested HDACi may be reducing PI3K/ AKT signalling, a pathway which is implicated in acquired and adaptive resistance to MAPK inhibitors. Western blot analysis of cell lysates after 24 hr of drug treatment revealed that although panobinostat (alone or in combination with encorafenib) did not alter pAKT levels, it reduced p-PRAS40, a direct target of AKT kinase activity (Fig. 6b) . To assess if direct PI3K inhibition would recapitulate the effects of HDACi, we treated CM150-post and CM145-post cell lines with the PI3K inhibitor BKM120. BKM120 decreased pAKT and p-PRAS40 and increased cell death when combined with encorafenib (Figs. 6c and 6d) . The cell death induced by combined PI3K 1 BRAF inhibition was less than that induced by combined HDAC 1 BRAF inhibition (Fig. 1a) and PI3K inhibition did not reduce XIAP or Bcl2 levels.
AKT mutants, such as AKT1 Q79K can confer resistance to BRAF inhibition 18 and it would be clinically relevant to know if combined HDAC 1 BRAF inhibition can be used in tumours with AKT-activating mutations. The CM-150-post cell line carries an acquired activating AKT1 E17K mutation (Supporting Information Table S1) , 46 yet is sensitive to the HDAC 1 BRAF inhibitor combination, suggesting this combination may be effective in the mutant-AKT setting. However, overexpression of a constitutively active myristoylated-AKT in CM150-pre cells partially abrogated the cell death induced by combined HDAC 1 BRAF inhibitor treatment (Supporting Information Figs. S5a and S5b). Although the myristoylated AKT expression may not be physiological, these data suggest the type and strength of mutations activating AKT alter the efficacy of combined HDAC 1 BRAF inhibitor treatment. A full investigation of this area remains to be performed.
HDAC inhibitors have been reported to inhibit PI3K signalling via a number of mechanisms, including reduction of RTKs. RTK signalling is associated with BRAFi resistance and may contribute to reactivation of the MAPK pathway and activation of the PI3K pathway. 9, 23, 47, 48 We treated all four BRAFi-resistant melanoma cells with panobinostat and/ or encorafenib for 24 hr and blotted for a number of RTK and RTK-related proteins (Fig. 6e) . Panobinostat alone or in combination with encorafenib reduced RTK proteins including AXL (CM142-post), ERBB2 and ERBB3 (CM150-, CM145-and CM142-post). Expression of individual RTKs was variable between the cell lines and we were unable to identify particular RTKs that were responsible for the resistance.
Discussion
The emergence of therapy resistance in melanoma patients treated with BRAF and MEK inhibitors is a significant clinical challenge and treatments that prevent the emergence of resistance, or that overcome established resistance is critical to improving the effectiveness of MAPK inhibitors. We have previously shown that HDACi potentiate the induction of apoptosis of melanoma cells by BRAF inhibitors. 49 They could also overcome the drug-resistance that most melanomas develop during treatment with BRAFi and MEKi but this applied only to some resistant melanomas. 50 In our study, we have examined the basis for the variable response of resistant melanoma to this drug combination.
We show that a precondition for response to combined HDAC and BRAF inhibition is the persistence of BRAFi activity that results in partial inhibition of MAPK signalling. Resistance mechanisms in our study included oncogenic
MEK1
E203K (CM143-post) and NRAS Q61H (SK-Mel28 BR2), which allowed strong MAPK activity despite BRAFi treatment. These cells did not respond well to combined treatment with HDACi and BRAFi. In contrast, cells where MAPK activity were strongly reduced following BRAF inhibition showed the best synergy with HDACi. These data suggest that HDACi would be better targeted to BRAFi-resistant melanoma not characterised by MAPK-reactivationreported to be between 10 and 40% of resistant tumours. 14, 15, 41 In addition, although MAPK inhibitor resistance is often accompanied by the reactivation of MAPK pathway, these resistant tumours may continue to respond partially to MAPK inhibition 6 and thus may also be sensitive to combination HDAC/BRAF inhibition.
The need for continued suppression of the MAPK pathway can be explained by its inhibitory effect on apoptosis by a number of Bcl-2 family related mechanisms, such as repression of BIM expression as well as phosphorylation of BIM, leading to its degradation. 51 This pathway also upregulates anti-apoptotic Bcl-2 and Bcl-XL proteins 52 and Mcl-1 by upregulation of Ets-1 downstream of ERK1/2. 53 Previous studies have reported that the Bcl-2 family proteins are major determinates of responses to BRAFi. 54, 55 BRAFi are known to increase BIM, leading to apoptosis, although this is partially offset by a reduction in NOXA. 42, 56 Despite these changes the alternative pathways are presumably able to provide survival signals which inhibit the apoptotic signals. Activation of the AKT pathway is a common mechanism of resistance to MAPKi -either due to activation by upstream RTKs or mutations/alterations in PTEN, PI3KCA, AKT or PI,P2 5 phosphatase. 15, 24, 57, 58 The mechanisms by which HDACi overcome resistance to BRAFi have not been fully resolved. HDACi not only alter the expression of thousands of genes, but also deacetylate non-histone proteins to alter their function. 59 We saw no evidence that HDACi directly inhibited MAPK signalling and most of our evidence points to effects on RTK and AKT signalling. A number of the resistant lines had high RTK expression including EGFR, ERBB2, ERBB3 and AXL, as reported by others. 60 RTK expression was variable between cell lines and in general only a subset was highly expressed in a single cell line. Some, particularly ERBB2; ERBB3 and AXL, were reduced by HDACi treatment, which was associated with moderate inhibition of AKT activity. Direct inhibition of PI3K signalling by BKM120 lead to a more potent inhibition of PI3K signalling, as shown by stronger reductions in pAKT and p-PRAS40, but induced less cell death than HDACi when combined with BRAFi. This observation suggests that while PI3K suppression by HDACi contributes to the synergy observed, it is only partially responsible. This hypothesis is supported by our observations that forced expression of activated AKT only partially protects against treatment with combined HDACi and BRAFi.
We considered whether other MAPK-independent resistance pathways may be involved such as CREB/MITF signalling, which has been reported to be reduced by HDACi. 25 In that study MITF was upregulated in the resistant lines and downregulated by HDACi as observed in our study. Downregulation of MITF may induce apoptosis via a number of mechanisms including reduced expression of Bcl-2 and BCL2A1. 44, 61 While MITF may contribute to the effects of HDACi, we observed synergy in cells that had low endogenous MITF expression, suggesting that reduced MITF expression may not be the central driver of resensitisation.
Irrespective of the signalling pathway involved, apoptosis of the cell lines HDACi was associated with variable reduction of XIAP and Bcl-XL and cell line dependent increases in BIM or NOXA. Increases in the latter prompted us to examine a possible role of c-Myc as Myc was shown to directly upregulate NOXA in melanoma and pancreatic cancers 43, 62 and also directly regulate BIM. 62, 63 Myc expression is frequently dysregulated and elevated in cancer cells, including melanoma. 64, 65 Myc affects biological functions such as cell division, growth and metabolism and can promote apoptosis if expressed highly. 63, 66 In our study, both BRAFi and HDACi decreased expression of Myc, in agreement with studies on MEK inhibitors in triple negative breast cancer. 67 However knockdown of Myc before drug treatment reduced the death induced combined HDAC/BRAFi treatment, suggesting that a simple reduction in Myc was not inducing cell death. While our studies show involvement of NOXA and BIM in HDACi-induced apoptosis, we could not correlate their levels to Myc expression.
In summary our study shows that the ability of HDACi to overcome resistance to selective BRAF inhibitors is confined to melanomas in which MAPK signalling remains responsive, albeit partially, to BRAF inhibition. Furthermore, resistance driven by PI3K pathway activation or over expression of RTKs such as ERBB2 and ERBB3 may be particular targets of HDACi. The mechanism by which HDACi induce apoptosis appears to be increased NOXA and reduced Bcl-2 family/ XIAP anti-apoptotic proteins, acting in concert with increased BIM levels that result from MAPK inhibition. Our results suggest panobinostat may have a role in combination with BRAF/MEK inhibitors in patients failing this treatment despite suppression of MAPK signalling the tumours. Reduction of Myc by HDACi may also be involved in the reversal of resistance and the role of Myc in resistance requires further study.
